ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014
Invasive gram-positive bacterial infection in cancer patients.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 96 citations in OpenAlex.
- Article
- Nasal colonization by potentially pathogenic bacteria, their antimicrobial susceptibility patterns, and risk factors for colonization among cancer patients at Dessie comprehensive specialized hospital, Northeast Ethiopia.BMC infectious diseases · 2025Article
- New scoring system combining WHO ordinal scale and MASCC score in predicting mortality of COVID-19 patients with malignancy and neutropenia: a retrospective cohort study.BMC infectious diseases · 2025Article
- Six-year retrospective analysis of the epidemiology and risk factors of multidrug-resistant bloodstream infections in oncology patients in Jiangxi, China.Microbiology spectrum · 2025Article
- Guillain-Barré Syndrome With Asymmetrical Weakness in a Patient With Charcot-Marie-Tooth Disease Type 1A.Cureus · 2025Article
- Fecal profiling reveals a common microbial signature for pancreatic cancer in Finnish and Iranian cohorts.Gut pathogens · 2025Article
- Malignant Fungating Wounds in Locally Aggressive Cutaneous Squamous Cell Carcinoma: A Case Series.Cureus · 2025Article
- Dynamic shifts in pathogen ecology of catheter-related bloodstream infections: temporal trends and ward-specific risk landscapes.Frontiers in medicine · 2025Article
- Marine Antimicrobial Peptide Epinecidin-1 Inhibits Proliferation Induced by Lipoteichoic acid and Causes cell Death in non-small cell lung cancer Cells via Mitochondria Damage.Probiotics and antimicrobial proteins · 2024Article
- Bloodstream infections in pediatric hematology/oncology patients: a single-center study in Wuhan.Frontiers in cellular and infection microbiology · 2024Article
- Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy.Microorganisms · 2023Article
- Enterotoxins A and B produced byHeliyon · 2023Article
- Mechanisms of bacterial inhibition and tolerance around cold atmospheric plasma.Applied microbiology and biotechnology · 2023Review
- Multi-drug resistant (MDR) and extensively drug-resistant (XDR) bacteraemia rates among cancer patients in an oncology hospital in eastern India: an 11-year retrospective observational study.Infection prevention in practice · 2023Article
- Bacterial Infections and Cancer: Exploring This Association And Its Implications for Cancer Patients.International journal of molecular sciences · 2023Review
- Exploitation of cantaloupe peels for bacterial cellulose production and functionalization with green synthesized Copper oxide nanoparticles for diverse biological applications.Scientific reports · 2022Article
- Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy.Cancers · 2022Review
- Adaptation of Bacteria to Antineoplastic Agents Involves Persister Cells and Increases Resistance to Antibiotics.Bioengineering (Basel, Switzerland) · 2022Article
- Synthesis, and docking studies of novel heterocycles incorporating the indazolylthiazole moiety as antimicrobial and anticancer agents.Scientific reports · 2022Article
- Characteristics and Outcomes of Bloodstream Infections in a Tertiary-Care Pediatric Hematology-Oncology Unit: A 10-Year Study.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Systematic studies have shown that gram-positive organisms are the leading cause of invasive bacterial disease in patients with cancer. A broad range of gram-positive bacteria cause serious infections in the cancer patient with the greatest burden of disease being due to staphylococci, streptococci, and enterococci. The evolution of cancer therapy and the changing epidemiology of major gram-positive pathogens mean that ongoing efforts are needed to understand and mitigate the impact of these bacteria in patients with malignancy. The development of novel antibacterials, optimization of treatment approaches, implementation of improved vaccines, and manipulation of the microbiome are all active areas of investigation in the goal of improving the survival of the cancer patient through amelioration of the disease burden of gram-positive bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.